Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7348175 | 0.82 | ECE1 (0.39) | — | |
| SCHEMBL7350029 | 0.82 | ECE1 (0.39) | — | |
| SCHEMBL21451319 | 0.81 | TGFBR1 (0.42) | TGFBR1MEN1CYP2D6CYP2C19KMT2A | |
| SCHEMBL21451274 | 0.81 | TGFBR1 (0.42) | TGFBR1MEN1CYP2D6CYP2C19KMT2A | |
| SCHEMBL23052779 | 0.81 | TGFBR1 (0.42) | TGFBR1MEN1CYP2D6CYP2C19KMT2A | |
| SCHEMBL3242285 | 0.80 | CTSS (0.41) | MEN1KMT2ACA12CA1CA9 | |
| SCHEMBL20999419 | 0.76 | — | — | |
| SCHEMBL12311713 | 0.76 | — | — | |
| SCHEMBL1577181 | 0.74 | TGFBR1 (0.38) | TGFBR1CA12CA1CA2CA9 | |
| SCHEMBL19719689 | 0.74 | TGFBR1 (0.38) | TGFBR1CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143612-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (US) | 2023-05-11 | — | — | US | disclosed |
| US-20210387941-A1 | Diphenyl-like Compound, Intermediate Thereof, Preparation Method Therefor, Pharmaceutical Composition Thereof And Uses Thereof | SHANGHAI MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) | 2021-12-16 | — | — | US | disclosed |
| US-11078192-B2 | Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. | 2021-08-03 | — | — | US | disclosed |
| US-20190308957-A1 | AROMATIC ACETYLENE OR AROMATIC ETHYLENE COMPOUND, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD (CN) | 2019-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143612-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | HAVCR2, HMBS, VHL | TGFBR1 2248/4885MEN1 896/4885CYP2D6 120/4885 |
| US-20210387941-A1 | Diphenyl-like Compound, Intermediate Thereof, Preparation Method Therefor, Pharmaceutical Composition Thereof And Uses Thereof | CD274, PDCD1LG2, PDCD1 | TGFBR1 649/4885MEN1 706/4885CYP2D6 543/4885 |
| US-20190308957-A1 | AROMATIC ACETYLENE OR AROMATIC ETHYLENE COMPOUND, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | PDCD1, CD274, PDCD1LG2 | TGFBR1 122/4885MEN1 668/4885CYP2D6 1659/4885 |
| US-11078192-B2 | Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof | PDCD1, CD274, PDCD1LG2 | TGFBR1 122/4885MEN1 668/4885CYP2D6 1659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.